Birchview Capital, LP Phathom Pharmaceuticals, Inc. Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 25,000 shares of PHAT stock, worth $339,000. This represents 0.25% of its overall portfolio holdings.
Number of Shares
25,000Holding current value
$339,000% of portfolio
0.25%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
137Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$169 Million6.31% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$101 Million12.93% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$56.1 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$47.4 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$39.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $531M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...